Axsome Therapeutics Inc.

08/19/2022 | Press release | Distributed by Public on 08/19/2022 04:55

Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults